id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2596338,7faec0a4-7ff2-4c47-bfc5-e71ea29c93c2,Q1,MICHAEL N. MCCARTY LAW OFFICE PLLC,401104300,AMERICAN MEDICAL TECHNOLOGISTS,2021,first_quarter,MMM,"Legislation affecting payment for clinical laboratory diagnostic tests, including but not limited to COVID-19 tests.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",10000,,0,0,2021-04-15T14:17:26.553000-04:00
2596339,7faec0a4-7ff2-4c47-bfc5-e71ea29c93c2,Q1,MICHAEL N. MCCARTY LAW OFFICE PLLC,401104300,AMERICAN MEDICAL TECHNOLOGISTS,2021,first_quarter,MED,"Support S. 236, the Tracking COVID-19 Variants Act; support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; monitor legislative efforts to regulated laboratory-developed tests (LDTs); support initiatives to improve COVID-19 testing supply chains.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",10000,,0,0,2021-04-15T14:17:26.553000-04:00